{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:36Z","timestamp":1791661896518,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515010935"],"award-info":[{"award-number":["2019A1515010935"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515011848"],"award-info":[{"award-number":["2019A1515011848"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["202201\u2013203"],"award-info":[{"award-number":["202201\u2013203"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877020"],"award-info":[{"award-number":["21877020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22007020"],"award-info":[{"award-number":["22007020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biopha.2022.113653","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T09:34:40Z","timestamp":1662543280000},"page":"113653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Identification of a novel PPAR\u03b3 modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation"],"prefix":"10.1016","volume":"154","author":[{"given":"Fangyuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113653_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.plipres.2005.12.002","article-title":"From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions","volume":"45","author":"Feige","year":"2006","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.biopha.2022.113653_bib2","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2022.113653_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0270001","article-title":"Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis","volume":"27","author":"Fajas","year":"2001","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113653_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/rp.56.1.239","article-title":"Peroxisome proliferator-activated receptors: from genes to physiology","volume":"56","author":"Kliewer","year":"2001","journal-title":"Recent. Prog. Horm. Res."},{"key":"10.1016\/j.biopha.2022.113653_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113653_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.biochem.70.1.341","article-title":"Peroxisome proliferator-activated receptor gamma and metabolic disease","volume":"70","author":"Willson","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2022.113653_bib7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3389\/fphar.2020.01285","article-title":"PPARgamma transcription deficiency exacerbates high-fat diet-induced adipocyte hypertrophy and insulin resistance in mice","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113653_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dsx.2014.09.015","article-title":"PPAR gamma gene--a review","volume":"9","author":"Janani","year":"2015","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.biopha.2022.113653_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.04.061","article-title":"Current anti-diabetic agents and their molecular targets: a review","volume":"152","author":"Kerru","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399405008793","article-title":"PPAR gamma as a metabolic regulator: insights from genomics and pharmacology","volume":"7","author":"Savage","year":"2005","journal-title":"Expert. Rev. Mol. Med."},{"key":"10.1016\/j.biopha.2022.113653_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2022.113653_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2004.03.012","article-title":"Peroxisome proliferator-activated receptor gamma in diabetes and metabolism","volume":"25","author":"Rangwala","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2022.113653_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.nutr.22.010402.102808","article-title":"PPAR(gamma) and glucose homeostasis","volume":"22","author":"Picard","year":"2002","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.biopha.2022.113653_bib14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","article-title":"Thiazolidinediones as antidiabetic agents: a critical review","volume":"77","author":"Nanjan","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113653_bib16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","article-title":"Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence","volume":"63","author":"Diamant","year":"2003","journal-title":"Drugs"},{"issue":"1292","key":"10.1016\/j.biopha.2022.113653_bib17","first-page":"1294","article-title":"Rosiglitazone approved for treatment of type 2 diabetes","volume":"56","author":"Miller","year":"1999","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.biopha.2022.113653_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0149-2918(00)80078-8","article-title":"A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus","volume":"23","author":"Chilcott","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2022.113653_bib19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2165\/00003495-200262120-00007","article-title":"Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus","volume":"62","author":"Wagstaff","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2022.113653_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.113653_bib21","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113653_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1089-3261(03)00020-5","article-title":"Hepatotoxicity of the thiazolidinediones","volume":"7","author":"Tolman","year":"2003","journal-title":"Clin. Liver. Dis."},{"key":"10.1016\/j.biopha.2022.113653_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the risk of bladder cancer: a meta-analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2022.113653_bib24","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113653_bib25","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113653_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.107.041202","article-title":"The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities","volume":"73","author":"Einstein","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113653_bib27","doi-asserted-by":"crossref","first-page":"16837","DOI":"10.1038\/s41598-017-17082-x","article-title":"Structures of PPARgamma complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113653_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0969-2126(01)00634-7","article-title":"Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family","volume":"9","author":"Cronet","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2022.113653_bib29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/me.2002-0217","article-title":"Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator","volume":"17","author":"Berger","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113653_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2015.02.043","article-title":"A step ahead of PPARgamma full agonists to PPARgamma partial agonists: therapeutic perspectives in the management of diabetic insulin resistance","volume":"755","author":"Chigurupati","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113653_bib31","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1021\/jm501155f","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) and ligand choreography: newcomers take the stage","volume":"58","author":"Garcia-Vallve","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10822-011-9446-9","article-title":"Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity","volume":"25","author":"Guasch","year":"2011","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.biopha.2022.113653_bib33","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm101360s","article-title":"Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators","volume":"55","author":"Pirat","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib34","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1038\/srep12222","article-title":"Selective targeting of PPARgamma by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency","volume":"5","author":"Zheng","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113653_bib35","first-page":"1094","article-title":"Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes","volume":"2007","author":"Gelman","year":"1771","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.113653_bib36","doi-asserted-by":"crossref","first-page":"8282","DOI":"10.1021\/acs.jmedchem.8b00835","article-title":"Identification of the first PPARalpha\/gamma dual agonist able to bind to canonical and alternative sites of PPARgamma and to inhibit its Cdk5-mediated phosphorylation","volume":"61","author":"Laghezza","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jsb.2019.07.007","article-title":"Exploring the mechanism of PPARgamma phosphorylation mediated by CDK5","volume":"207","author":"Ribeiro Filho","year":"2019","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.biopha.2022.113653_bib38","doi-asserted-by":"crossref","first-page":"11168","DOI":"10.1038\/s41598-019-47672-w","article-title":"Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARgamma phosphorylation","volume":"9","author":"Jang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113653_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101030","article-title":"The therapeutic potential of inhibiting PPARgamma phosphorylation to treat type 2 diabetes","volume":"297","author":"Frkic","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/acsmedchemlett.1c00715","article-title":"Discovery by virtual screening of an inhibitor of CDK5-Mediated PPARgamma phosphorylation","volume":"13","author":"O'Mahony","year":"2022","journal-title":"Acs. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2022.113653_bib41","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.chembiol.2021.04.019","article-title":"Endogenous vitamin E metabolites mediate allosteric PPARgamma activation with unprecedented co-regulatory interactions","volume":"28","author":"Willems","year":"2021","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.biopha.2022.113653_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174562","article-title":"PPAR-gamma agonists: Potential modulators of autophagy in obesity","volume":"912","author":"Faghfouri","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113653_bib43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/md17040242","article-title":"Astaxanthin as a Peroxisome Proliferator-Activated Receptor (PPAR) modulator: its therapeutic implications","volume":"17","author":"Choi","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.biopha.2022.113653_bib44","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1021\/acs.jmedchem.9b01786","article-title":"A selective modulator of peroxisome proliferator-activated receptor gamma with an unprecedented binding mode","volume":"63","author":"Hanke","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","article-title":"Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): a review","volume":"92","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113653_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2020.1703952","article-title":"Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present","volume":"30","author":"Takada","year":"2020","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.biopha.2022.113653_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113653_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113653_bib49","doi-asserted-by":"crossref","first-page":"26618","DOI":"10.1074\/jbc.M114.566794","article-title":"A novel non-agonist peroxisome proliferator-activated receptor gamma (PPARgamma) ligand UHC1 blocks PPARgamma phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity","volume":"289","author":"Choi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib50","doi-asserted-by":"crossref","first-page":"28169","DOI":"10.1074\/jbc.M111.332106","article-title":"GQ-16, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, promotes insulin sensitization without weight gain","volume":"287","author":"Amato","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib51","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","article-title":"Partial agonists activate PPARgamma using a helix 12 independent mechanism","volume":"15","author":"Bruning","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2022.113653_bib52","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1021\/acs.jmedchem.0c00048","article-title":"Insights into PPARgamma phosphorylation and its inhibition mechanism","volume":"63","author":"Montanari","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2020.08.016","article-title":"Obesity-Linked PPARgamma S273 phosphorylation promotes insulin resistance through growth differentiation factor 3","volume":"32","author":"Hall","year":"2020","journal-title":"Cell. Metab."},{"key":"10.1016\/j.biopha.2022.113653_bib54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cell.2011.09.050","article-title":"Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity","volume":"147","author":"Li","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113653_bib55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPARgamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.113653_bib56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/adt.2015.692","article-title":"Development of an ELISA for high-throughput screening of inhibitors of Cdk5-Mediated PPARgamma phosphorylation","volume":"14","author":"Prokoph","year":"2016","journal-title":"Assay. Drug. Dev. Technol."},{"key":"10.1016\/j.biopha.2022.113653_bib57","doi-asserted-by":"crossref","first-page":"8330","DOI":"10.1021\/acs.jpcb.5b04269","article-title":"Molecular recognition of PPARgamma by kinase Cdk5\/p25: Insights from a combination of protein-protein docking and adaptive biasing force simulations","volume":"119","author":"Mottin","year":"2015","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.biopha.2022.113653_bib58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejmech.2016.08.027","article-title":"New telmisartan-derived PPARgamma agonists: Impact of the 3D-binding mode on the pharmacological profile","volume":"124","author":"Obermoser","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPARgamma partial agonism","volume":"2015","author":"Kroker","year":"2015","journal-title":"Ppar. Res."},{"key":"10.1016\/j.biopha.2022.113653_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105860","article-title":"Identification of the anti-fungal drug fenticonazole nitrate as a novel PPARgamma-modulating ligand with good therapeutic index: Structure-based screening and biological validation","volume":"173","author":"Ma","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2022.113653_bib61","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1039\/C9SC05487A","article-title":"Identification and structural insight of an effective PPARgamma modulator with improved therapeutic index for anti-diabetic drug discovery","volume":"11","author":"Jiang","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.biopha.2022.113653_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1074\/jbc.M111.294785","article-title":"Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors","volume":"287","author":"Malapaka","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113542","article-title":"Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARgamma with potential anti-diabetic efficacy","volume":"222","author":"Huang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib64","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/acs.jmedchem.0c01512","article-title":"Tetrazanbigen derivatives as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists: design, synthesis, structure-activity relationship, and anticancer activities","volume":"64","author":"Gan","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib65","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1021\/acs.jmedchem.9b02150","article-title":"l-thyroxin and the nonclassical thyroid hormone TETRAC are potent activators of PPARgamma","volume":"63","author":"Gellrich","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ab.2012.03.005","article-title":"Protocol for effective differentiation of 3T3-L1 cells to adipocytes","volume":"425","author":"Zebisch","year":"2012","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2022.113653_bib67","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.113653_bib68","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cmet.2021.03.004","article-title":"Placental superoxide dismutase 3 mediates benefits of maternal exercise on offspring health","volume":"33","author":"Kusuyama","year":"2021","journal-title":"Cell. Metab."},{"key":"10.1016\/j.biopha.2022.113653_bib69","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1021\/acs.jmedchem.1c01941","article-title":"Overcoming paradoxical kinase priming by a novel MNK1 inhibitor","volume":"65","author":"Bou-Petit","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113653_bib70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cardiores.2006.07.014","article-title":"Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma","volume":"72","author":"Imayama","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2022.113653_bib71","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2022.113653_bib72","doi-asserted-by":"crossref","first-page":"41487","DOI":"10.1038\/srep41487","article-title":"Identification of a novel selective PPARgamma ligand with a unique binding mode and improved therapeutic profile in vitro","volume":"7","author":"Yi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113653_bib73","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41467-020-14750-x","article-title":"A molecular switch regulating transcriptional repression and activation of PPARgamma","volume":"11","author":"Shang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113653_bib74","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1152\/physrev.2001.81.3.1269","article-title":"Nuclear hormone receptors and gene expression","volume":"81","author":"Aranda","year":"2001","journal-title":"Physiol. Rev."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:34:21Z","timestamp":1791660861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222010423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":74,"alternative-id":["S0753332222010423"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113653","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a novel PPAR\u03b3 modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113653"}}